Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19521142 | 0.92 | ACHE (0.40) | HTR2AHTR2CHTR2BACHEMEN1 | |
| SCHEMBL21954384 | 0.83 | ACHE (0.45) | HTR2AHTR2CHTR2BACHE | |
| SCHEMBL803170 | 0.82 | ACHE (0.41) | ACHEMEN1KMT2A | |
| SCHEMBL19521139 | 0.82 | TMEM97 (0.41) | HTR2AHTR2CHTR2BACHE | |
| SCHEMBL27856415 | 0.80 | ACHE (0.39) | HTR2AHTR2CHTR2BACHEPTGDR | |
| SCHEMBL27838563 | 0.80 | ACHE (0.39) | HTR2AHTR2CHTR2BACHEPTGDR | |
| SCHEMBL18497279 | 0.80 | ACHE (0.40) | HTR2AHTR2CHTR2BACHEPTGDR | |
| SCHEMBL3645107 | 0.76 | ACHE (0.51) | HTR2AHTR2CHTR2BACHE | |
| SCHEMBL1576021 | 0.76 | ACHE (0.51) | HTR2AHTR2CHTR2BACHE | |
| SCHEMBL30896364 | 0.76 | ACHE (0.51) | HTR2AHTR2CHTR2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | HTR2A 475/4885HTR2C 549/4885HTR2B 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.